Literature DB >> 21389127

A respiratory syncytial virus replicon that is noncytotoxic and capable of long-term foreign gene expression.

Olga Malykhina1, Mark A Yednak, Peter L Collins, Paul D Olivo, Mark E Peeples.   

Abstract

Respiratory syncytial virus (RSV) infection of most cultured cell lines causes cell-cell fusion and death. Cell fusion is caused by the fusion (F) glycoprotein and is clearly cytopathic, but other aspects of RSV infection may also contribute to cytopathology. To investigate this possibility, we generated an RSV replicon that lacks all three of its glycoprotein genes and so cannot cause cell-cell fusion or virus spread. This replicon includes a green fluorescent protein gene and an antibiotic resistance gene to enable detection and selection of replicon-containing cells. Adaptive mutations in the RSV replicon were not required for replicon maintenance. Cells containing the replicon could be cloned and passaged many times in the absence of antibiotic selection, with 99% or more of the cells retaining the replicon after each cell division. Transient expression of the F and G (attachment) glycoproteins supported the production of virions that could transfer the replicon into most cell lines tested. Since the RSV replicon is not toxic to these cultured cells and does not affect their rate of cell division, none of the 8 internal viral proteins, the viral RNA transcripts, or the host response to these molecules or their activities is cytopathic. However, the level of replicon genome and gene expression is controlled in some manner well below that of complete virus and, as such, might avoid cytotoxicity. RSV replicons could be useful for cytoplasmic gene expression in vitro and in vivo and for screening for compounds active against the viral polymerase.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21389127      PMCID: PMC3126208          DOI: 10.1128/JVI.02399-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Persistence of respiratory syncytial virus in macrophages alters phagocytosis and pro-inflammatory cytokine production.

Authors:  A Guerrero-Plata; E Ortega; B Gomez
Journal:  Viral Immunol       Date:  2001       Impact factor: 2.257

2.  Functional significance of alternate phosphorylation in Sendai virus P protein.

Authors:  C j Hu; K C Gupta
Journal:  Virology       Date:  2000-03-15       Impact factor: 3.616

3.  An improved method for recovery of F-defective Sendai virus expressing foreign genes from cloned cDNA.

Authors:  Takahiro Hirata; Akihiro Iida; Takako Shiraki-Iida; Kaio Kitazato; Atsushi Kato; Yoshiyuki Nagai; Mamoru Hasegawa
Journal:  J Virol Methods       Date:  2002-07       Impact factor: 2.014

4.  Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene.

Authors:  S Techaarpornkul; N Barretto; M E Peeples
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Respiratory syncytial virus matrix protein associates with nucleocapsids in infected cells.

Authors:  R Ghildyal; J Mills; M Murray; N Vardaxis; J Meanger
Journal:  J Gen Virol       Date:  2002-04       Impact factor: 3.891

6.  Nontransmissible virus-like particle formation by F-deficient sendai virus is temperature sensitive and reduced by mutations in M and HN proteins.

Authors:  Makoto Inoue; Yumiko Tokusumi; Hiroshi Ban; Takumi Kanaya; Tsuyoshi Tokusumi; Yoshiyuki Nagai; Akihiro Iida; Mamoru Hasegawa
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

7.  Mutations in hepatitis C virus RNAs conferring cell culture adaptation.

Authors:  V Lohmann; F Körner; A Dobierzewska; R Bartenschlager
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

8.  Efficient initiation of HCV RNA replication in cell culture.

Authors:  K J Blight; A A Kolykhalov; C M Rice
Journal:  Science       Date:  2000-12-08       Impact factor: 47.728

9.  Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication.

Authors:  Keril J Blight; Jane A McKeating; Charles M Rice
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

10.  Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps.

Authors:  Nicola Ternette; Daniela Stefanou; Seraphin Kuate; Klaus Uberla; Thomas Grunwald
Journal:  Virol J       Date:  2007-06-05       Impact factor: 4.099

View more
  15 in total

1.  Novel diversity-oriented synthesis-derived respiratory syncytial virus inhibitors identified via a high throughput replicon-based screen.

Authors:  Jeremy R Duvall; Lynn VerPlank; Barbara Ludeke; Sarah M McLeod; Maurice D Lee; Karthick Vishwanathan; Carol A Mulrooney; Sebastian Le Quement; Qin Yu; Michelle A Palmer; Paul Fleming; Rachel Fearns; Michael A Foley; Christina A Scherer
Journal:  Antiviral Res       Date:  2016-04-06       Impact factor: 5.970

2.  Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates.

Authors:  Thomas Grunwald; Matthias Tenbusch; Reiner Schulte; Katharina Raue; Hans Wolf; Drew Hannaman; Rik L de Swart; Klaus Uberla; Christiane Stahl-Hennig
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

3.  Mechanism of action for respiratory syncytial virus inhibitor RSV604.

Authors:  SreeRupa Challa; Andrew D Scott; Olga Yuzhakov; Ying Zhou; Choi Lai Tiong-Yip; Ning Gao; Jason Thresher; Qin Yu
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

4.  The respiratory syncytial virus polymerase can perform RNA synthesis with modified primers and nucleotide analogs.

Authors:  Barbara Ludeke; Rachel Fearns
Journal:  Virology       Date:  2019-11-06       Impact factor: 3.616

Review 5.  Targeting RSV with vaccines and small molecule drugs.

Authors:  Heather M Costello; William C Ray; Supranee Chaiwatpongsakorn; Mark E Peeples
Journal:  Infect Disord Drug Targets       Date:  2012-04

6.  Characterization of a respiratory syncytial virus L protein inhibitor.

Authors:  Choi-Lai Tiong-Yip; Lisa Aschenbrenner; Kenneth D Johnson; Robert E McLaughlin; Jun Fan; SreeRupa Challa; Hui Xiong; Qin Yu
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

7.  The Interferon Type I/III Response to Respiratory Syncytial Virus Infection in Airway Epithelial Cells Can Be Attenuated or Amplified by Antiviral Treatment.

Authors:  K M McCutcheon; R Jordan; M E Mawhorter; S L Noton; J G Powers; R Fearns; T Cihlar; M Perron
Journal:  J Virol       Date:  2015-11-25       Impact factor: 5.103

8.  GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.

Authors:  Michel Perron; Kirsten Stray; April Kinkade; Dorothy Theodore; Gary Lee; Eugene Eisenberg; Michael Sangi; Brian E Gilbert; Robert Jordan; Pedro A Piedra; Geoffery L Toms; Richard Mackman; Tomas Cihlar
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

9.  Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B.

Authors:  Jodi Dufner-Beattie; Andrew O'Guin; Stephanie O'Guin; Aaron Briley; Bin Wang; Jennifer Balsarotti; Robert Roth; Gale Starkey; Urszula Slomczynska; Amine Noueiry; Paul D Olivo; Charles M Rice
Journal:  Antimicrob Agents Chemother       Date:  2014-04-07       Impact factor: 5.191

10.  Distinct and overlapping roles of Nipah virus P gene products in modulating the human endothelial cell antiviral response.

Authors:  Michael K Lo; Mark E Peeples; William J Bellini; Stuart T Nichol; Paul A Rota; Christina F Spiropoulou
Journal:  PLoS One       Date:  2012-10-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.